Articles tagged "Antilymphocyte antibodies"

2016 American Transplant Congress
Absence of Acute Allograft Rejection in the Early Post Operative Period in a Full Face VCA Recipient with a Positive B-Cell Flow Cytometric Crossmatch Utilizing an Induction Immunosuppression Regimen Including Anti-thymocyte and Anti-CD20 Agents.
B. Gelb,³ M. Plana,¹ D. Dadhania,² M. Suthanthiran,² J. Diaz-Siso,¹ E. Rogriguez.¹
¹Plastic and Reconstructive Surgery, NYU Langone, New York; ²Rogosin Institute, New York; ³Transplant Surgery, NYU Langone, New York.
Background: The presence of donor-specific antibodies (DSA) to human leukocyte antigen (HLA) convey increased risk of allograft rejection. Patients suffering full-thickness burns to the face…
2016 American Transplant Congress
Kidney Transplantation in HIV Patients: Effect of Race on the Choice of Anti-Thymocyte Globulin Induction Immunosuppression.
M. Casey, T. Aijaz, X. Wen, S. Rehman, A. Santos, E. Thomas, K. Andreoni, K. Womer.
University of Florida, Gainesville, FL.
Introduction: HIV positive status is a well-known risk factor for acute rejection (AR) in kidney transplant recipients (KTR). In the United States, the majority of…
2016 American Transplant Congress
Surveillance Biopsy Findings with Alemtuzumab (ALZ) Induction in Kidney Transplantation.
H. Madariaga,¹ R. Ugarte,¹ C. Drachenberg,² N. Costa,¹ B. Thomas,¹ J. Bromberg,³ M. Weir,¹ A. Haririan.¹
¹Department of Medicine, University of Maryland Medical Center, Baltimore, MD; ²Department of Pathology, University of Maryland Medical Center, Baltimore, MD; ³Department of Surgery, University of Maryland Medical Center, Baltimore, MD.
The risk of subclinical histological changes in renal allografts with ALZ induction is not well defined. Hence, we performed a retrospective analysis of 527 surveillance…
2016 American Transplant Congress
Continuous Antithymocyte Globulin (rATG) for Treatment of Renal Allograft Rejection: Preliminary Analysis of a Prospective, Randomized Trial.
S. Patel, R. Knight, S. Kuten, J. Nolte, A. Gaber.
Houston Methodist Hospital, Houston, TX.
Intravenous (IV) rATG for acute rejection (AR) is primarily given on an inpatient basis due to its daily administration, IV access requirement, and monitoring. The…
2016 American Transplant Congress
CD45RO+/CD62L- Effector Memory T Cells Mediate Depletion Resistant Allograft Rejection in Intestinal Transplant Recipients.
C. Cosentino, J. Kaiser, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.
MedStar Georgetown Transplant Institute, Washington DC.
A. A high risk of acute cellular rejection (ACR) is one of the key factors limiting intestinal transplantation (ITx). An extremely poor prognosis is related…
2016 American Transplant Congress
Limiting Helper Functions of CD4 T Cells Improves Efficacy of Induction Therapy without Compromising Responses to Third Party Antigens.
K. Ayasoufi, V. Gorbacheva, F. Ran, A. Valujskikh.
Cleveland Clinic, Cleveland.
Antibody mediated lymphocyte depletion is commonly used in clinical transplantation. However, memory T cells undermine the efficacy of lymphoablative induction therapies in sensitized transplant recipients.…
2016 American Transplant Congress
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.
T. Jouve,^1,2 G. Rigault,^1,2 B. Janbon,¹ R. Tetaz,¹ N. Terrier,¹ D. Masson,³ L. Rostaing,^1,2 P. Malvezzi.¹
¹Nephrology and Kidney Transplantation Unit, Grenoble University Hospital, Grenoble, France, Metropolitan; ²Grenoble Alpes University, Grenoble, France, Metropolitan; ³Etablissement Francais du Sang, Grenoble, France, Metropolitan.
Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…
2016 American Transplant Congress
Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.
S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, F. Al Ammary, D. Segev.
Johns Hopkins, Baltimore, MD.
Antithymocyte globulin (ATG) is recommended over IL-2 receptor antagonist (IL2) in high-risk recipients for induction immunosuppression. However, “high-risk” status has not been defined in an…
2016 American Transplant Congress
Outcomes in Elderly Renal Transplant Recipients Using Thymoglobulin or Interleukin-2 Receptor Antagonist Induction.
N. Jasiak,¹ J. Thielke,¹ J. Chen,² N. Hilal,¹ S. Salah,¹ D. Wu,¹ E. Benedetti,² P. West-Thielke.^1,2
¹Pharmacy, University of Illinois, Chicago; ²Transplant Surgery, University of Illinois, Chicago.
Background: Approximately 20% of all renal transplants performed in the US in 2014 occurred in elderly patients. Elderly patients are known to be at higher…
2016 American Transplant Congress
Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.
N. Jasiak,¹ C. Stromayer,¹ J. Thielke,¹ J. Chen,² J. Chen,¹ B. Talon,¹ R. Rubin-Tobar,¹ E. Benedetti,² P. West-Thielke.^1,2
¹Pharmacy, University of Illinois, Chicago; ²Transplant Surgery, University of Illinois, Chicago, IL.
Background: Dosing of rabbit anti-thymocyte globulin (rATG) induction in renal transplant recipients is highly variable by transplant center. Optimizing rATG dose becomes extremely important for…